Posted by Michael Wonder on 17 Apr 2018
Rigel announces FDA approval of Tavalisse (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia in adult patients
17 April 2018 - Tavalisse offers first-in-class treatment with unique mechanism of action.
Rigel Pharmaceuticals today announced that the U.S. FDA approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Tavalisse is an oral spleen tyrosine kinase inhibitor that targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing an important new treatment option for adult patients with chronic ITP. Rigel plans to launch Tavalisse in the United States in late May 2018.
